Related Experiment Video
Updated: Aug 6, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Macrophage membrane camouflaged biomimetic nanomedicine for normalizing electrical dysfunction and inflammation
Houhua He1, Yingying Jiang1, Yiqiong Zhang1
1Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Department of Cardiology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Department of Oncology, Chongqing University Jiangjin Hospital, Department of neurology, Chongqing University Three Gorges Hospital, School of Medicine, Chongqing, 400044, China.
Abstract:
Atrial fibrillation (AF), the common sustained tachyarrhythmia in clinical practice, is characterized by a pathophysiology with electrical dysfunction and inflammation. To overcome the challenges of low bioavailability, short pharmacokinetic half-life and severe adverse effects of Amiodarone (AMD), a macrophage membrane-biomimetic nanotherapeutic platform (MM@AMDNPs) was developed for enhancing the target delivery and sustained AMD release. Given the inherited biological activity from macrophage, MM@AMDNPs is able to specifically localize to AF-associated inflammatory lesion, enabling interference with electrical remodeling while mitigating AMD-related pulmonary toxicity, i.e., compared with the uncoated nanoparticles, MM@AMDNPs prolongs 2.03-fold blood circulation half-life, enhances 1.7-fold target accumulation at AF lesions, reduces macrophage phagocytosis by 65.5%, alleviates AF inducibility from 100% to 20%, shortens AF duration from 132.8 ± 26.2 s to 0.8 ± 1.8 s at 4 h post-administration, normalizes the inflammatory marker iNOS and fibrotic marker TGF-β1 in lung tissues without any significant pulmonary histopathological injury. Hence, MM@AMDNPs represents a promising therapeutic platform for safe and effective antiarrhythmic therapy.
